Michael S. Leibowitz
University of Pennsylvania
6 Papers
1 Citations
Michael S. Leibowitz is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Fibroblast activation protein, alpha & Cardiac fibrosis. The author has an hindex of 4, co-authored 6 publications. Previous affiliations of Michael S. Leibowitz include Children's Hospital of Philadelphia.
Chat about Author
Papers
Targeting cardiac fibrosis with engineered T cells.
Haig Aghajanian,Toru Kimura,Joel G. Rurik,Aidan S. Hancock,Michael S. Leibowitz,Michael S. Leibowitz,Li Li,John Scholler,James Monslow,Albert C. Lo,Wei Han,Tao Wang,Kenneth Bedi,Michael Morley,Ricardo A. Linares Saldana,Nikhita A. Bolar,Kendra McDaid,Charles-Antoine Assenmacher,Cheryl L. Smith,Dagmar Wirth,Carl H. June,Kenneth B. Margulies,Rajan Jain,Ellen Puré,Steven M. Albelda,Jonathan A. Epstein +25 more
TL;DR: This work demonstrates the efficacy of redirected T cell immunotherapy to specifically target pathological cardiac fibrosis in mice and finds that cardiac fibroblasts that express a xenogeneic antigen can be effectively targeted and ablated by adoptive transfer of antigen-specific CD8+ T cells.
Lactate Limits T Cell Proliferation via the NAD(H) Redox State.
William J. Quinn,Jing Jiao,Tara TeSlaa,Jason Stadanlick,Zhonglin Wang,Liqing Wang,Tatiana Akimova,Alessia Angelin,Patrick M. Schäfer,Michelle D. Cully,Caroline Perry,Piotr K. Kopinski,Lili Guo,Ian A. Blair,Louis R. Ghanem,Michael S. Leibowitz,Wayne W. Hancock,Edmund K. Moon,Matthew H. Levine,Evgeniy Eruslanov,Douglas C. Wallace,Joseph A. Baur,Ulf H. Beier +22 more
TL;DR: It is reported that nicotinamide adenine dinucleotide (NAD+), which is reduced to NADH by lactate dehydrogenase in lactate-rich conditions, is a key point of metabolic control in T cells and directly targeting the redox state may be a useful approach for developing novel immunotherapies in cancer and therapeutic immunosuppression.
230
Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-β and chronic bleomycin-induced fibrosis.
Toru Kimura,James Monslow,Astero Klampatsa,Michael S. Leibowitz,Jing Sun,Maria Liousia,Patrick Woodruff,Edmund K. Moon,Leslie Todd,Ellen Puré,Steven M. Albelda +10 more
TL;DR: It is found that loss of FAP+ cells exacerbated fibrosis in the bleomycin model, a phenotype largely recapitulated by the genetic deletion of F AP, indicating that FAP plays a role in this model.
38
Standardization of prophylactic platelet transfusion dosing in a pediatric oncology population: a quality improvement project.
Michael S. Leibowitz,Michael S. Leibowitz,Heather Wolfe,Heather Wolfe,Andrea Flynn,Andrea Flynn,Angela J. Waanders,Angela J. Waanders,Caroline Burlingame,Brenna Aumaier,David F. Friedman,Michele P. Lambert,Michele P. Lambert +12 more
TL;DR: Wide variation in platelet dosing is found at this institution due to lack of guidance and support for standardized dosing.
7
Author Correction: Targeting cardiac fibrosis with engineered T cells.
Haig Aghajanian,Toru Kimura,Joel G. Rurik,Aidan S. Hancock,Michael S. Leibowitz,Michael S. Leibowitz,Li Li,John Scholler,James Monslow,Albert C. Lo,Wei Han,Tao Wang,Kenneth Bedi,Michael Morley,Ricardo A. Linares Saldana,Nikhita A. Bolar,Kendra McDaid,Charles-Antoine Assenmacher,Cheryl L. Smith,Dagmar Wirth,Carl H. June,Kenneth B. Margulies,Rajan Jain,Ellen Puré,Steven M. Albelda,Jonathan A. Epstein +25 more
TL;DR: An Amendment to this paper has been published and can be accessed via a link at the top of the paper.